ASCO and EHA Overview of Top Multiple Myeloma Abstracts and Posters

ASCO and EHA Overview of Top Multiple Myeloma Abstracts and Posters

ASCO and EHA Overview of Top Multiple Myeloma Abstracts and Posters

In this video, IMF Chief Medical Officer Dr. Joseph Mikhael (TGen, City of Hope Cancer Center – Scottsdale, AZ, USA) provides an overview of the top myeloma-related abstracts from the 2021 American Clinical Society of Oncology (ASCO) and 2021 European Hematology Association (EHA) annual meetings.

He discusses optimal induction therapies for myeloma, the continuous use of autologous stem cell transplant as a standard of care in myeloma, the role of maintenance therapy, and best options for high-risk multiple myeloma. Dr. Mikhael also covers CAR T-cell therapy and bispecific therapies.

He points to the results of MAIA study, a late-breaking abstract from the EHA meeting, to shed light on long-term management of the disease.

_______________
Improving Lives Through Research and Patient Care

In the United States, an estimated 32,270 new multiple myeloma cases will be diagnosed in 2021. 159,985 new myeloma cases are diagnosed yearly.

Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.

Subscribe to our channel: https://www.youtube.com/c/IMFMyeloma

Visit our website at: https://www.myeloma.org

Find us online:
Facebook: @myeloma | https://facebook.com/myeloma
Twitter: @IMFMyeloma | https://twitter.com/IMFmyeloma
Instagram: @imfmyeloma | https://www.instagram.com/imfmyeloma
LinkedIn: https://www.linkedin.com/company/international-myeloma-foundation

Support the IMF! http://bit.ly/WskQHC
Category
Nonprofits & Activism
License
Standard YouTube License

Leave a Reply

Your email address will not be published. Required fields are marked *